USP8突变状态联合术后皮质醇水平预测库欣病复发
该研究纳入107例经病理确诊的促肾上腺皮质激素腺瘤患者,用Sanger测序检测USP8体细胞突变,并以多因素Cox模型、ROC曲线和Kaplan-Meier分析评估复发预测因素。中位随访65个月,13例(12.6%)复发,USP8突变型肿瘤复发率显著高于野生型(26.5% vs 5.8%,P=.009)。USP8突变联合术后晨血清皮质醇(MSC)或1mg地塞米松抑制试验(DST)可提高阳性预测值,阴性预测值达98%和100%。
要点
- USP8突变型肿瘤复发率26.5%,显著高于野生型的5.8%(P=.009)。
- USP8突变、术后高MSC和高1mg DST与5年复发风险升高相关。
- USP8突变联合术后MSC或1mg DST可提高复发阳性预测值。
核心结论
- USP8突变状态联合术后晨血清皮质醇或1mg地塞米松抑制试验是长期缓解的独立预测因素,可能有助于对预后不佳风险患者进行分层。
研究设计与样本
- 纳入107例经病理确诊的促肾上腺皮质激素腺瘤患者,采用Sanger测序检测USP8体细胞突变,用多因素Cox模型估计复发预测因素,并行受试者工作特征曲线和Kaplan-Meier分析。
主要发现
- 13例(12.6%)患者复发,术后平均随访65个月。
- USP8突变型肿瘤复发率显著高于USP8野生型肿瘤(26.5% vs 5.8%;P=.009)。
- 多因素Cox模型显示USP8突变、术后高晨血清皮质醇和高1mg地塞米松抑制试验与5年复发风险升高相关。
- Kaplan-Meier分析显示USP8突变合并术后晨血清皮质醇>2.5 μg/dL或1mg地塞米松抑制试验>0.78 μg/dL的患者更易复发(log-rank P<.001)。
- 联合USP8突变与术后晨血清皮质醇时阴性预测值为98%、阳性预测值从33%提高至55%;联合USP8突变与1mg地塞米松抑制试验时阴性预测值为100%、阳性预测值从47%提高至86%。
关键数值与推荐
- 术后晨血清皮质醇阈值>2.5 μg/dL。
- 1mg地塞米松抑制试验阈值>0.78 μg/dL。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: The ubiquitin-specific protease 8 (USP8) gene mutations are the most common driver changes in Cushing disease (CD). However, few studies have investigated the association between USP8 mutation and recurrence, and the results have been inconclusive. OBJECTIVE: To identify the predictors of recurrence and evaluate the prognostic role of USP8 mutation. METHODS: One hundred and seven patients with pathologically confirmed corticotroph adenomas were included. Somatic USP8 mutations were identified using Sanger sequencing. Recurrence predictors were estimated using multivariate Cox models, followed by receiver operating characteristic curves and Kaplan-Meier analysis. RESULTS: Thirteen patients (12.6%) experienced recurrence, with a mean follow-up period of 65 months after surgery. The recurrence rate was significantly higher in USP8-mutated tumors than in USP8 wildtype tumors (26.5% vs 5.8%; P = .009). Multivariate Cox models revealed that USP8 mutation, high postsurgical morning serum cortisol (MSC), and high 1-mg dexamethasone suppression test (DST) were associated with an increased 5-year recurrence risk. Furthermore, Kaplan-Meier survival analysis showed that patients with USP8 mutation, combined with either high postsurgical MSC (>2.5 μg/dL) or high 1-mg DST (>0.78 μg/dL), were more prone to recurrence (log-rank P < .001). The negative predictive values were 98% and 100%, while the positive predictive values improved from 33% to 55% and from 47% to 86%, respectively. CONCLUSION: Our study corroborates USP8 mutational status in combination with postsurgical MSC or 1-mg DST as independent predictors of long-term remission, highlighting their potential role in stratifying patients at risk for suboptimal outcomes.
引用
- Zhou W, Zheng S, Ye L, et al. The USP8 Mutational Status in Combination With Postsurgical Cortisol Levels for Predicting Recurrence of Cushing Disease. J Clin Endocrinol Metab. 2025. PMID: 40424186. doi:10.1210/clinem/dgaf269
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。